Mitsubishi UFJ Asset Management Co. Ltd. Raises Stock Position in Amgen Inc. $AMGN

Mitsubishi UFJ Asset Management Co. Ltd. lifted its position in shares of Amgen Inc. (NASDAQ:AMGN) by 4.7% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 1,295,157 shares of the medical research company’s stock after acquiring an additional 57,649 shares during the quarter. Mitsubishi UFJ Asset Management Co. Ltd. owned 0.24% of Amgen worth $424,345,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also modified their holdings of the company. Board of the Pension Protection Fund acquired a new position in Amgen during the fourth quarter worth $26,000. Olistico Wealth LLC purchased a new position in shares of Amgen in the fourth quarter valued at $33,000. Cloud Capital Management LLC acquired a new position in shares of Amgen during the 3rd quarter worth $34,000. Ares Financial Consulting LLC acquired a new position in shares of Amgen during the 4th quarter worth $34,000. Finally, Saranac Partners Ltd purchased a new stake in shares of Amgen in the 3rd quarter worth about $37,000. Institutional investors and hedge funds own 76.50% of the company’s stock.

Amgen News Roundup

Here are the key news stories impacting Amgen this week:

• Positive Sentiment: Amgen announced a $300 million additional U.S. manufacturing investment (Puerto Rico) to expand biologics capacity and strengthen supply-chain resilience; investors tend to see such capital spending as supportive of long-term growth and reliability. Article Title
• Neutral Sentiment: Erste Group reaffirmed a “hold” rating on AMGN, signaling no change in near-term analyst conviction and limiting directional impact from that broker. Article Title
• Neutral Sentiment: Market/sector headwinds: healthcare stocks were softer in recent trading sessions, a background factor that can mute upside for AMGN even as company-specific news emerges. Article Title
• Negative Sentiment: Competitive risk: Viridian Therapeutics reported encouraging results for its chronic thyroid eye disease program, a potential rival to Amgen’s Tepezza — the data lifted Viridian shares and raises the probability of increased market competition for Tepezza sales over time. Article Title
• Negative Sentiment: Guggenheim trimmed its price target on AMGN to $340 (from $351) while keeping a Neutral rating — a modest lowering of upside that can cap near-term analyst-driven buying. Article Title

Insiders Place Their Bets

In other Amgen news, SVP Nancy A. Grygiel sold 1,237 shares of the stock in a transaction on Monday, May 4th. The stock was sold at an average price of $323.73, for a total transaction of $400,454.01. Following the transaction, the senior vice president owned 7,009 shares of the company’s stock, valued at $2,269,023.57. This represents a 15.00% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this link. Company insiders own 0.85% of the company’s stock.

Amgen Price Performance

NASDAQ:AMGN opened at $329.59 on Wednesday. Amgen Inc. has a 12-month low of $261.43 and a 12-month high of $391.29. The firm has a market cap of $177.87 billion, a price-to-earnings ratio of 22.94, a price-to-earnings-growth ratio of 3.08 and a beta of 0.44. The company’s 50-day moving average is $357.16 and its two-hundred day moving average is $341.35. The company has a current ratio of 1.26, a quick ratio of 0.90 and a debt-to-equity ratio of 5.65.

Amgen (NASDAQ:AMGN) last issued its quarterly earnings results on Thursday, April 30th. The medical research company reported $5.15 EPS for the quarter, topping analysts’ consensus estimates of $4.77 by $0.38. The business had revenue of $8.62 billion during the quarter, compared to the consensus estimate of $8.58 billion. Amgen had a net margin of 20.96% and a return on equity of 137.41%. The company’s quarterly revenue was up 5.8% compared to the same quarter last year. During the same period in the previous year, the firm posted $4.90 earnings per share. Amgen has set its FY 2026 guidance at 21.700-23.100 EPS. Research analysts expect that Amgen Inc. will post 22.45 EPS for the current year.

Amgen Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Friday, June 5th. Shareholders of record on Friday, May 15th will be paid a $2.52 dividend. This represents a $10.08 annualized dividend and a yield of 3.1%. The ex-dividend date of this dividend is Friday, May 15th. Amgen’s payout ratio is presently 70.15%.

Analyst Ratings Changes

AMGN has been the subject of several recent research reports. Wells Fargo & Company raised their target price on shares of Amgen from $375.00 to $390.00 and gave the company an “equal weight” rating in a report on Thursday, March 19th. Sanford C. Bernstein lowered shares of Amgen from an “outperform” rating to a “market perform” rating and set a $335.00 price target on the stock. in a research report on Tuesday, January 20th. Wall Street Zen cut shares of Amgen from a “buy” rating to a “hold” rating in a research note on Saturday, April 25th. Truist Financial lifted their price objective on Amgen from $325.00 to $327.00 and gave the stock a “hold” rating in a research report on Friday, May 1st. Finally, Daiwa Securities Group increased their target price on Amgen from $370.00 to $410.00 and gave the company an “outperform” rating in a report on Tuesday, February 10th. One analyst has rated the stock with a Strong Buy rating, thirteen have given a Buy rating, fifteen have assigned a Hold rating and two have given a Sell rating to the stock. According to MarketBeat.com, Amgen presently has an average rating of “Hold” and an average price target of $357.12.

Amgen Profile

Amgen Inc (NASDAQ: AMGN) is a global biotechnology company founded in 1980 and headquartered in Thousand Oaks, California. The company focuses on discovering, developing, manufacturing and delivering human therapeutics that address serious illnesses. Amgen’s work centers on biologic medicines derived from cellular and molecular biology, with an emphasis on translating advances in human genetics and protein science into therapies for patients.

Amgen’s commercial portfolio has historically included biologics used in oncology, supportive care, nephrology, bone health and cardiovascular disease.